Log In

 

Company Name : Takeda Pharmaceutical Company Limited

Wednesday, January 24, 2018 12:20PM IST (6:50AM GMT)

(BW)(TAKEDA-PHARMACEUTICAL)

Takeda Recognized as a Global 100 Most Sustainable Corporation for Third Consecutive Year


Osaka, Japan

Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to be named by Corporate Knights as one of the 2018 Global 100 Most Sustainable Corporations in the World (Global 100) for the third consecutive year. This distinction is based on 17 key performance indicators including financial management, clean revenue, and supplier performance. Takeda performed in the top 25% on innovation capacity, receiving notable recognition for its leadership diversity. Global 100 companies in 2018 represent the top 1.3% in the world on sustainability performance. The Index launched in 2005; results are disclosed annually at the World Economic Forum in Davos.

 

As a LEAD company within the United Nations Global Compact, Takeda’s established track record in sustainability is guided by long-term international targets such as the Sustainable Development Goals (SDGs). Takeda is the only Japanese pharmaceutical company and among the four companies from Japan to make the final 100 in 2018, and one of just ten pharmaceutical companies in the world to be listed.

 

“Takeda is honored to be recognized once again for our commitment to sustainability, particularly alongside such distinguished global corporations,” said Haruhiko Hirate, Corporate Communications & Public Affairs Officer. “We strive to create and maximize long-term economic, social, and environmental value worldwide, led by our unique and diverse corporate governance, through our corporate social responsibility (CSR), which contributes to the lasting health of patients worldwide through long-term investments in disease prevention, capacity building, and access to healthcare. As a company, Takeda strives for Better Health and a Brighter Future for people worldwide through leading innovation in medicine, together with the global community.”

 

In addition to the Global 100 Index, Takeda is recognized by multiple Socially Responsible Investment (SRI) valuations.
 

Name of Index/Investment
Universe/Ratings

 

Company/
Organization Conducting
Assessment

  Country   Honors Awarded
Dow Jones Sustainability Asia Pacific Index   S&P Dow Jones Indices   US   8th consecutive year
FTSE4Good Global Index   FTSE Russel   UK   13th consecutive year
Ethibel EXCELLENCE Investment Register   Forum Ethibel   BEL   three times
Prime Status   Oekom   GER   first time
 

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited (TOKYO:4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.

 

Additional information about Takeda is available through its Sustainable Value Report, https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/.

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Media Contacts:
Japanese Media
Takeda Pharmaceutical Company Limited
Satoko Imai, +81-3-3278-2037
satoko.imai@takeda.com


More News from Takeda Pharmaceutical Company Limited

28/09/2018 12:25PM

Takeda Establishes Record Date for the Extraordinary General Meeting of Shareholders

Further to the announcement of the recommended acquisition of Shire plc (“Shire”) on May 8, 2018 (“the Acquisition”), Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda” or ...

25/09/2018 7:05PM

Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC

– ALTA-1L Met its Primary Endpoint Showing Superiority in Blinded Independent Review Committee-Assessed Progression-Free Survival Compared to Crizotinib – – Data Will Be Presented During the ...

22/09/2018 10:20AM

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib

Takeda Pharmaceutical Company Limited (TSE: 4502) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full ...

Similar News

16/10/2018 8:12PM

PotNetwork Holdings, Inc. Releases PCAOB Fully Audited and Reviewed Financial Statements under Its Registration as an SEC Reporting Company

PotNetwork Holdings, Inc. (OTC Pink:POTN)has successfully filed its Form 10 registration statement with the U.S. Securities and Exchange Commission (“SEC”), which included independent third party PCAOB ...

No Image

16/10/2018 3:52PM Image

On the Occasion of World Food Day, NatureFresh Launches Pro Health Oil - NatureFresh Acti Heart

NatureFresh, the home-grown brand of Cargill’s food business in India has extended its offering into premium health oil space with the launch of NatureFresh Acti Heart, at a press conference in New Delhi, today.